JPWO2019140273A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019140273A5 JPWO2019140273A5 JP2020538029A JP2020538029A JPWO2019140273A5 JP WO2019140273 A5 JPWO2019140273 A5 JP WO2019140273A5 JP 2020538029 A JP2020538029 A JP 2020538029A JP 2020538029 A JP2020538029 A JP 2020538029A JP WO2019140273 A5 JPWO2019140273 A5 JP WO2019140273A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- seq
- variable region
- siglec
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616317P | 2018-01-11 | 2018-01-11 | |
| US62/616,317 | 2018-01-11 | ||
| PCT/US2019/013316 WO2019140273A1 (en) | 2018-01-11 | 2019-01-11 | Anti-siglec-7 antibodies having reduced effector function |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021511298A JP2021511298A (ja) | 2021-05-06 |
| JPWO2019140273A5 true JPWO2019140273A5 (https=) | 2022-02-07 |
| JP2021511298A5 JP2021511298A5 (https=) | 2022-02-07 |
| JP7342005B2 JP7342005B2 (ja) | 2023-09-11 |
Family
ID=67219179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538029A Active JP7342005B2 (ja) | 2018-01-11 | 2019-01-11 | エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11912766B2 (https=) |
| EP (1) | EP3737410A4 (https=) |
| JP (1) | JP7342005B2 (https=) |
| AU (1) | AU2019208025A1 (https=) |
| CA (1) | CA3087968A1 (https=) |
| WO (1) | WO2019140273A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2996059A1 (en) | 2015-08-28 | 2017-03-09 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
| MX2020013172A (es) | 2018-06-08 | 2021-03-29 | Alector Llc | Anticuerpos anti-siglec-7 y sus metodos de uso. |
| WO2023091512A2 (en) * | 2021-11-16 | 2023-05-25 | Allakos, Inc. | Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9 |
| WO2023192992A2 (en) * | 2022-03-31 | 2023-10-05 | The Wistar Institute Of Anatomy And Biology | Bispecific natural killer engagers that target siglec-7 |
| WO2023192993A2 (en) * | 2022-03-31 | 2023-10-05 | The Wistar Institute Of Anatomy And Biology | Antibodies against human siglec-7 and use thereof for immunotherapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007120815A2 (en) | 2006-04-12 | 2007-10-25 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
| CN101687924A (zh) * | 2007-07-04 | 2010-03-31 | 株式会社未来创药研究所 | 抗Muc17抗体 |
| PE20190658A1 (es) * | 2012-02-24 | 2019-05-08 | Abbvie Stemcentrx Llc | Moduladores y metodos de empleo novedosos |
| CA2896076C (en) * | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| MX383594B (es) * | 2014-08-07 | 2025-03-14 | Daiichi Sankyo Co Ltd | Anticuerpo anti-orai1. |
| JP2017532025A (ja) * | 2014-09-10 | 2017-11-02 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 交差反応性ｓｉｇｌｅｃ抗体 |
| CA2996059A1 (en) | 2015-08-28 | 2017-03-09 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
| BR112018010172A2 (pt) * | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| WO2017123745A1 (en) | 2016-01-12 | 2017-07-20 | Palleon Pharma Inc. | Use of siglec-7 or siglec-9 antibodies for the treatment of cancer |
| WO2017153433A1 (en) * | 2016-03-08 | 2017-09-14 | Innate Pharma | Siglec neutralizing antibodies |
| JP7137563B2 (ja) * | 2016-08-05 | 2022-09-14 | アラコス，インコーポレイティド | がん治療用の抗Ｓｉｇｌｅｃ－７抗体 |
-
2019
- 2019-01-11 WO PCT/US2019/013316 patent/WO2019140273A1/en not_active Ceased
- 2019-01-11 AU AU2019208025A patent/AU2019208025A1/en not_active Abandoned
- 2019-01-11 EP EP19739010.7A patent/EP3737410A4/en not_active Withdrawn
- 2019-01-11 JP JP2020538029A patent/JP7342005B2/ja active Active
- 2019-01-11 CA CA3087968A patent/CA3087968A1/en active Pending
- 2019-01-11 US US16/961,197 patent/US11912766B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511298A5 (https=) | ||
| US12152076B2 (en) | Bispecific and monospecific antibodies using novel anti-PD-1 sequences | |
| JP7344858B2 (ja) | Ｆｃ含有ポリペプチドの安定化 | |
| US20250206821A1 (en) | Method for in vivo generation of multispecific antibodies from monospecific antibodies | |
| US20250361325A1 (en) | Method for generating multispecific antibodies from monospecific antibodies | |
| CN108699136B (zh) | 结合cd3和psma的异二聚抗体 | |
| JP2024009818A5 (https=) | ||
| JP2020522266A5 (https=) | ||
| CN107406512A (zh) | 结合cd3和cd38的异二聚体抗体 | |
| CN114174344B (zh) | 工程改造铰链区以驱动抗体二聚化 | |
| US20220119549A1 (en) | Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof | |
| JPWO2021030657A5 (https=) | ||
| JPWO2021019389A5 (https=) | ||
| JPWO2019140273A5 (https=) | ||
| US20240150471A1 (en) | Natural killer cell antibodies with increased adcc activity | |
| JPWO2020128870A5 (https=) | ||
| JPWO2023026235A5 (https=) | ||
| JPWO2022047243A5 (https=) | ||
| JPWO2023156409A5 (https=) | ||
| US12612468B2 (en) | Engineering the hinge region to drive antibody dimerization | |
| JPWO2023023465A5 (https=) | ||
| RU2022110238A (ru) | Индуцирующий цитотоксичность терапевтический агент | |
| WO2025245176A1 (en) | Multispecific antibody constructs | |
| NZ729157B2 (en) | Anti-trem2 antibodies and methods of use thereof | |
| JPWO2022268983A5 (https=) |